AstraZeneca Operating Margin 1992-2025 | AZN

Current and historical operating margin for AstraZeneca (AZN) over the last 10 years. The current operating profit margin for AstraZeneca as of June 30, 2025 is 24.84%.
AstraZeneca Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2025-06-30 $56.50B $11.32B 20.04%
2025-03-31 $54.98B $10.56B 19.21%
2024-12-31 $54.07B $10.00B 18.50%
2024-09-30 $51.21B $9.20B 17.97%
2024-06-30 $49.13B $9.05B 18.42%
2024-03-31 $47.61B $8.76B 18.40%
2023-12-31 $45.81B $8.19B 17.88%
2023-09-30 $45.00B $8.05B 17.90%
2023-06-30 $44.49B $7.35B 16.51%
2023-03-31 $43.84B $5.43B 12.38%
2022-12-31 $44.35B $3.76B 8.47%
2022-09-30 $45.15B $2.37B 5.25%
2022-06-30 $44.04B $-0.55B -1.25%
2022-03-31 $41.49B $0.04B 0.09%
2021-12-31 $37.42B $1.06B 2.82%
2021-09-30 $32.82B $2.84B 8.64%
2021-06-30 $29.53B $5.68B 19.24%
2021-03-31 $27.58B $5.84B 21.16%
2020-12-31 $26.62B $5.16B 19.39%
2020-09-30 $25.87B $4.25B 16.44%
2020-06-30 $25.70B $3.84B 14.93%
2020-03-31 $25.25B $3.05B 12.07%
2019-12-31 $24.38B $2.92B 11.99%
2019-09-30 $24.14B $3.42B 14.19%
2019-06-30 $23.07B $3.52B 15.25%
2019-03-31 $22.40B $3.79B 16.91%
2018-12-31 $22.09B $3.39B 15.33%
2018-09-30 $21.45B $3.00B 13.97%
2018-06-30 $22.34B $3.29B 14.74%
2018-03-31 $22.24B $3.46B 15.54%
2017-12-31 $22.47B $3.68B 16.37%
2017-09-30 $22.27B $5.52B 24.80%
2017-06-30 $21.74B $5.40B 24.85%
2017-03-31 $22.29B $4.78B 21.45%
2016-12-31 $23.00B $4.90B 21.31%
2016-09-30 $23.82B $3.46B 14.52%
2016-06-30 $24.06B $3.60B 14.96%
2016-03-31 $24.77B $4.22B 17.04%
2015-12-31 $24.71B $4.11B 16.65%
2015-09-30 $25.03B $2.68B 10.70%
2015-06-30 $25.69B $2.05B 7.97%
2015-03-31 $26.14B $2.23B 8.54%
2014-12-31 $26.55B $2.14B 8.05%
2014-09-30 $26.77B $1.90B 7.08%
2014-06-30 $26.41B $3.06B 11.59%
2014-03-31 $25.88B $3.15B 12.17%
2013-12-31 $25.81B $3.71B 14.38%
2013-09-30 $26.15B $6.27B 23.97%
2013-06-30 $26.58B $6.72B 25.27%
2013-03-31 $27.01B $7.39B 27.34%
2012-12-31 $27.97B $8.15B 29.13%
2012-09-30 $29.35B $8.35B 28.46%
2012-06-30 $30.88B $10.46B 33.87%
2012-03-31 $32.65B $11.55B 35.39%
2011-12-31 $33.59B $12.80B 38.09%
2011-09-30 $33.55B $13.46B 40.11%
2011-06-30 $33.24B $11.60B 34.90%
2011-03-31 $32.99B $11.50B 34.88%
2010-12-31 $33.27B $11.49B 34.55%
2010-09-30 $33.60B $11.63B 34.61%
2010-06-30 $33.90B $12.37B 36.48%
2010-03-31 $33.68B $12.04B 35.74%
2009-12-31 $32.80B $11.54B 35.19%
2009-09-30 $32.05B $10.38B 32.38%
2009-06-30 $31.63B $9.62B 30.43%
2009-03-31 $31.63B $9.38B 29.67%
2008-12-31 $31.60B $8.62B 27.28%
2008-09-30 $31.58B $14.99B 47.47%
2008-06-30 $30.95B $19.75B 63.81%
2008-03-31 $30.30B $19.20B 63.36%
2007-12-31 $29.59B $19.09B 64.53%
2007-09-30 $28.57B $12.24B 42.85%
2007-06-30 $27.94B $7.07B 25.32%
2007-03-31 $27.26B $7.26B 26.65%
2006-12-31 $26.48B $7.13B 26.93%
2006-09-30 $25.61B $7.38B 28.81%
2006-06-30 $24.88B $7.05B 28.34%
2006-03-31 $24.39B $6.80B 27.87%
2005-12-31 $23.95B $6.31B 26.34%
2005-09-30 $23.46B $6.29B 26.81%
2005-06-30 $22.94B $5.84B 25.44%
2005-03-31 $22.10B $5.14B 23.28%
2004-12-31 $21.43B $4.77B 22.26%
2004-09-30 $20.50B $4.00B 19.52%
2004-06-30 $20.04B $3.83B 19.12%
2004-03-31 $19.19B $3.69B 19.24%
2003-12-31 $18.85B $3.91B 20.75%
2003-09-30 $18.87B $4.03B 21.37%
2003-06-30 $18.42B $3.92B 21.30%
2003-03-31 $18.37B $4.09B 22.27%
2002-12-31 $18.05B $3.98B 22.02%
2002-09-30 $17.59B $3.39B 19.27%
2002-06-30 $17.19B $3.39B 19.71%
2002-03-31 $16.91B $3.33B 19.69%
2001-12-31 $16.48B $3.08B 18.70%
2001-09-30 $16.18B $6.91B 42.67%
2001-06-30 $16.53B $10.28B 62.20%
2001-03-31 $16.40B $13.30B 81.12%
2000-12-31 $17.01B $17.01B 100.00%
2000-06-30 $13.11B $13.11B 100.00%
2000-03-31 $12.95B $12.95B 100.00%
1998-12-31 $15.40B $15.40B 100.00%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $218.471B $44.351B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
Merck (MRK) United States $270.018B 37.87
AbbVie (ABBV) United States $264.086B 11.85
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12